Olwen Hahn to Proportional Hazards Models
This is a "connection" page, showing publications Olwen Hahn has written about Proportional Hazards Models.
Connection Strength
0.097
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.066
-
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 05; 94:115-125.
Score: 0.032